Transaction · 0001134657-26-000015

EVNIN LUKE

EVNIN LUKE, DIR, reported an open-market or private sale at Werewolf Therapeutics, Inc. involving 32556.000000 shares for an estimated $14650.20. Reported holdings after the transaction were 622579.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SDIR
HOWLWerewolf Therapeutics, Inc.
Filing timeMay 29
Trade dateMay 29, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$0.45
Pre-filing
1mo ago +51.1%1w ago -2.2%1d ago +0.0%
Returns since
7d -13.3%30d -28.9%90d +93.3%180d +93.3%1y +93.3%

HOWL price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
HOWL since 2026-05-29Filed 97 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001134657-26-000015
Common Stock
Transaction date
May 29, 2026
Filed May 29, 2026, 10:51 PM · 0d delay
Shares
32.5k sh
$45 per share
Estimated value
-$1.46M
Computed from shares × price
Holdings after
622k sh
Indirect · See Footnotes

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
10b5-1 Detected
-6score
Filing-only score

-6

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.

  2. F2

    The shares were sold as follows: 8,663 by MPM Asset Management LLC ("AM LLC"), 54,692 by MPM BioVentures 2014, L.P. ("BV 2014"), 3,648 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,883 by MPM Ass…

  3. F3

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.46 to $0.49705 inclusive. The Reporting Person undertakes to provi…

  4. F4

    MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations…

  5. F5

    The shares are held as follows: 73,157 by AM LLC, 461,914 by BV 2014, 30,807 by BV 2014(B), 15,896 by AM BV2014 and 101,059 by MPM OIF.

  6. F6

    The shares were sold as follows: 2,968 by AM LLC, 18,736 by BV 2014, 1,250 by BV 2014(B), 645 by AM BV2014 and 4,099 by MPM OIF.

  7. F7

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.455 to $0.4858 inclusive. The Reporting Person undertakes to provi…

  8. F8

    The shares are held as follows: 70,189 by AM LLC, 443,178 by BV 2014, 29,557 by BV 2014(B), 15,251 by AM BV2014 and 96,960 by MPM OIF.

  9. F9

    The shares were sold as follows: 3,488 by AM LLC, 22,023 by BV 2014, 1,469 by BV 2014(B), 758 by AM BV2014 and 4,818 by MPM OIF.

  10. F10

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.44 to $0.4557 inclusive. The Reporting Person undertakes to provid…

  11. F11

    The shares are held as follows: 66,701 by AM LLC, 421,155 by BV 2014, 28,088 by BV 2014(B), 14,493 by AM BV2014 and 92,142 by MPM OIF.

Original filing · 0001134657-26-000015
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

HOWL